This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (78)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Drug Therapy  • Drug Therapy, Other  • Immunology  • Immunologic Disorders  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Implications for Clinical Management

Michael M. Lederman, MD; Hernan Valdez, MD

JAMA. 2000;284:223-228.

Recent dramatic decreases in acquired immunodeficiency syndrome–related mortality are largely due to the introduction of highly active antiretroviral therapy (HAART). Although immune restoration due to suppression of human immunodeficiency virus (HIV) replication is a critical determinant of these trends, the magnitude of immune restoration seen after treatment with HAART varies substantially among treated persons and is generally incomplete. Nonetheless, even partial immune restoration is sufficient to provide protection from most major opportunistic infections; these risks can be largely predicted by the number of circulating CD4 cells. Limited data suggest that treatment earlier during the course of HIV infection may result in greater preservation of immune function, though this has not been studied in great detail. Preliminary studies performed among persons with multidrug-resistant virus whose treatment regimens are failing suggest that there is likely a benefit to continuation of therapy that may be related to diminished pathogenicity of drug-resistant virus. As deaths related to opportunistic infections diminish, the spectrum of causes of mortality in HIV infection is changing. Except for Kaposi sarcoma, there is insufficient information to conclude that the risks of non-Hodgkin lymphoma and other malignancies are diminishing among persons with HIV infection. How much immune restoration will be enough to ensure long-term survival in persons with HIV infection remains an open question.

Author Affiliations: Center for AIDS Research, Case Western Reserve University School of Medicine and Division of Infectious Diseases, University Hospitals of Cleveland, Cleveland, Ohio.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Immunologic and Virologic Effects of Subcutaneous Interleukin 2 in Combination With Antiretroviral Therapy: A Randomized Controlled Trial
Richard T. Davey, Jr, Robert L. Murphy, Frank M. Graziano, Stephen L. Boswell, Andrew T. Pavia, Margarita Cancio, Jeffrey P. Nadler, Doreen G. Chaitt, Robin L. Dewar, David K. Sahner, Anne-Marie Duliege, William B. Capra, Wai-Ping Leong, Martin A. Giedlin, H. Clifford Lane, and James O. Kahn
JAMA. 2000;284(2):183-189.
ABSTRACT | FULL TEXT  

Interleukin 2 Treatment for HIV Infection
Joel Blankson and Robert F. Siliciano
JAMA. 2000;284(2):236-238.
EXTRACT | FULL TEXT  

July 12, 2000
JAMA. 2000;284(2):249-250.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Viral Suppression and Immune Restoration in the Gastrointestinal Mucosa of Human Immunodeficiency Virus Type 1-Infected Patients Initiating Therapy during Primary or Chronic Infection.
Guadalupe et al.
J. Virol. 2006;80:8236-8247.
ABSTRACT | FULL TEXT  

Eosinophilic Folliculitis: Before and After the Introduction of Antiretroviral Therapy
Rajendran et al.
Arch Dermatol 2005;141:1227-1231.
ABSTRACT | FULL TEXT  

Effect of a Protease Inhibitor-Induced Genetic Bottleneck on Human Immunodeficiency Virus Type 1 env Gene Populations
Kitrinos et al.
J. Virol. 2005;79:10627-10637.
ABSTRACT | FULL TEXT  

Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?
Marchetti et al.
J Antimicrob Chemother 2005;55:401-409.
ABSTRACT | FULL TEXT  

Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS Malignancy Consortium and IM862 Study Team
Noy et al.
JCO 2005;23:990-998.
ABSTRACT | FULL TEXT  

Treatment of Recurring Cutaneous Drug Reactions in Patients With Human Immunodeficiency Virus 1 Infection: A Series of 3 Cases
Dolev et al.
Arch Dermatol 2004;140:1051-1053.
FULL TEXT  

Novel Single-Cell-Level Phenotypic Assay for Residual Drug Susceptibility and Reduced Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1
Zhang et al.
J. Virol. 2004;78:1718-1729.
ABSTRACT | FULL TEXT  

IL-7 Stimulates T Cell Renewal Without Increasing Viral Replication in Simian Immunodeficiency Virus-Infected Macaques
Nugeyre et al.
J. Immunol. 2003;171:4447-4453.
ABSTRACT | FULL TEXT  

Cardiac surgery in patients infected with the human immunodeficiency virus
Trachiotis et al.
Ann. Thorac. Surg. 2003;76:1114-1118.
ABSTRACT | FULL TEXT  

Sarcoidosis Following HIV Infection: Evidence for CD4+ Lymphocyte Dependence
Morris et al.
Chest 2003;124:929-935.
ABSTRACT | FULL TEXT  

Positive Regulation of CXCR4 Expression and Signaling by Interleukin-7 in CD4+ Mature Thymocytes Correlates with Their Capacity To Favor Human Immunodeficiency X4 Virus Replication
Schmitt et al.
J. Virol. 2003;77:5784-5793.
ABSTRACT | FULL TEXT  

Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Goldie et al.
Arch Intern Med 2002;162:921-928.
ABSTRACT | FULL TEXT  

Pulmonary Manifestations of HIV Infection in the Era of Highly Active Antiretroviral Therapy
Wolff and O'Donnell
Chest 2001;120:1888-1893.
ABSTRACT | FULL TEXT  

Interleukin-7 and infection itself by human immunodeficiency virus 1 favor virus persistence in mature CD4+CD8{-}CD3+ thymocytes through sustained induction of Bcl-2
Guillemard et al.
Blood 2001;98:2166-2174.
ABSTRACT | FULL TEXT  

Interleukin 2 Treatment for HIV Infection
Blankson and Siliciano
JAMA 2000;284:236-238.
FULL TEXT